Influence of lidocaine on ouabain-induced inotropic response in rat atria

Area of Science:

• Pharmacology
• Cardiovascular Physiology
• Biochemistry

Background:

• Ouabain is a cardiac glycoside used to treat heart failure, but its narrow therapeutic index poses toxicity risks.
• Lidocaine, an antiarrhythmic drug, has shown potential in modulating cardiac ion channel activity.

Purpose of the Study:

• To investigate the protective effects of lidocaine against ouabain-induced toxicity in rat atria.
• To elucidate the underlying mechanisms of lidocaine's interaction with ouabain binding sites and its impact on cardiac contractility.

Main Methods:

• Isolated rat atria were used to assess the effects of lidocaine and ouabain on contractility and electrophysiology.
• Binding studies were performed to determine the affinity and number of ouabain binding sites in the presence of lidocaine.
• Pharmacological agents like KB-R7943 and flunarizine were used to block Na(+)-Ca(2+) exchange and channels.

Main Results:

• Lidocaine broadened the therapeutic range of ouabain, reducing its toxicity by increasing Na(+)-K(+)-ATPase sensitivity and decreasing high-affinity binding sites.
• Lidocaine suppressed ouabain-induced positive inotropic effects and arrhythmias by reducing low-affinity binding sites.
• Blockade of Na(+)-Ca(2+) exchange mimicked lidocaine's protective effects, suggesting a role for calcium handling.

Conclusions:

• Lidocaine exhibits a protective effect against ouabain toxicity in rat atria, likely through interaction with ouabain binding sites.
• The findings suggest that lidocaine modulates cardiac contractility via mechanisms involving Na(+)-K(+)-ATPase and Na(+)-Ca(2+) exchange.